Urgent Workup for Infiltrative Cardiomyopathy Required
Based on the echocardiographic findings of concentric hypertrophy with increased myocardial echogenicity, reduced global longitudinal strain (12%), and mildly thickened valve leaflets, immediate evaluation for cardiac amyloidosis is mandatory. 1
Immediate Diagnostic Testing
Screen for Plasma Cell Dyscrasia (Within 48-72 Hours)
The combination of concentric hypertrophy, increased echogenicity ("sparkling" myocardium), reduced GLS with preserved EF (54%), and thickened valves raises strong suspicion for infiltrative disease, particularly amyloidosis 1. Order immediately:
- Serum and urine protein electrophoresis with immunofixation
- Serum free light chain (sFLC) assay with kappa/lambda ratio 1
These tests are critical to differentiate AL amyloidosis (requiring urgent hematology referral) from ATTR amyloidosis. An abnormal sFLC ratio or monoclonal protein presence indicates AL amyloidosis and necessitates urgent hematology consultation within days 1.
Advanced Cardiac Imaging
Cardiac MRI with late gadolinium enhancement (LGE) should be performed within 2-4 weeks 1. Look for:
- Diffuse subendocardial or transmural LGE pattern
- Elevated native T1 mapping times
- Increased extracellular volume expansion
- These findings strongly support amyloidosis diagnosis 1
The reduced GLS of 12% (normal >18-20%) with preserved EF is highly characteristic of infiltrative cardiomyopathy and correlates with myocardial fibrotic burden 2, 3. This pattern—particularly when GLS is severely reduced (<15%)—is associated with worse outcomes and higher risk of ventricular arrhythmias 4, 3.
Nuclear Imaging (If Plasma Cell Dyscrasia Excluded)
If serum/urine studies show no monoclonal protein, proceed with technetium-99m pyrophosphate (PYP) scintigraphy to diagnose ATTR amyloidosis non-invasively 1. Positive uptake (Perugini grade 2-3) confirms ATTR without need for biopsy.
If PYP is positive, perform TTR genetic testing to distinguish hereditary ATTR (hATTR) from wild-type ATTR (wtATTR) 1.
Additional Recommended Testing
Biomarkers
- Troponin and BNP/NT-proBNP levels 1—typically elevated in cardiac amyloidosis and correlate with prognosis
- These help assess disease severity and guide monitoring
Exclude Alternative Diagnoses
The differential includes:
- Hypertrophic cardiomyopathy (HCM): However, the uniform concentric pattern, increased echogenicity, and thickened valves are atypical for HCM 5. HCM typically shows asymmetric septal hypertrophy (≥15mm) without valve thickening 5
- Hypertensive heart disease: The mildly enlarged ascending aorta and concentric hypertrophy could suggest hypertension 6, but increased echogenicity and valve thickening point toward infiltration
- Fabry disease or other storage disorders: Consider if family history or systemic symptoms present 7
Electrocardiogram Review
Look for low voltage (paradoxical given wall thickness), pseudo-infarct pattern, or conduction abnormalities—all suggestive of amyloidosis 7.
Clinical Implications and Monitoring
Risk Stratification
The GLS of 12% places this patient at significantly increased risk for:
- Heart failure progression
- Ventricular arrhythmias (4-fold increased risk with GLS >-10%) 4, 3
- Sudden cardiac death 4, 3
Follow-up Imaging
If amyloidosis is confirmed, repeat echocardiography every 3-6 months initially to assess:
- Progression of wall thickness
- Development of restrictive physiology
- Worsening diastolic function
- Changes in GLS (further decline indicates disease progression) 8
Therapeutic Considerations
If ATTR amyloidosis confirmed, newer disease-modifying therapies (tafamidis for wtATTR, gene silencers for hATTR) may be indicated. If AL amyloidosis, urgent chemotherapy is required 1.
Critical Pitfalls to Avoid
- Do not delay plasma cell dyscrasia screening—AL amyloidosis requires urgent treatment and has worse prognosis than ATTR 1
- Do not assume hypertensive heart disease based solely on concentric hypertrophy—the increased echogenicity and valve thickening are red flags 1
- Do not rely on EF alone—the preserved EF (54%) masks significant myocardial dysfunction evident on GLS 4, 2
- Do not perform endomyocardial biopsy initially if non-invasive testing is diagnostic 1
The combination of imaging findings strongly suggests infiltrative disease requiring systematic evaluation to prevent delayed diagnosis and optimize treatment outcomes.